ABIOMED, Inc. (NASDAQ:ABMD) has been assigned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $400.50.
A number of brokerages recently issued reports on ABMD. Zacks Investment Research cut shares of ABIOMED from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. BidaskClub upgraded shares of ABIOMED from a “sell” rating to a “hold” rating in a report on Friday, March 22nd. ValuEngine cut shares of ABIOMED from a “hold” rating to a “sell” rating in a report on Tuesday, May 7th. BTIG Research restated a “buy” rating on shares of ABIOMED in a report on Tuesday, May 7th. Finally, SunTrust Banks restated a “buy” rating and set a $340.00 price objective on shares of ABIOMED in a report on Friday, May 3rd.
Shares of ABMD traded up $5.56 on Monday, reaching $260.49. 480,850 shares of the company’s stock were exchanged, compared to its average volume of 562,108. The stock has a market cap of $11.54 billion, a PE ratio of 72.36, a P/E/G ratio of 2.02 and a beta of 0.39. The stock’s 50 day simple moving average is $261.12. ABIOMED has a 12 month low of $228.00 and a 12 month high of $459.75.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.07 by $0.53. The business had revenue of $207.08 million during the quarter, compared to the consensus estimate of $218.88 million. ABIOMED had a net margin of 33.66% and a return on equity of 20.32%. ABIOMED’s revenue for the quarter was up 18.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.80 earnings per share. On average, equities research analysts expect that ABIOMED will post 4.5 earnings per share for the current fiscal year.
In related news, Director Martin P. Sutter sold 4,664 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $259.97, for a total transaction of $1,212,500.08. Following the completion of the transaction, the director now owns 192,550 shares in the company, valued at $50,057,223.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 3.50% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Sontag Advisory LLC acquired a new position in shares of ABIOMED in the fourth quarter valued at approximately $25,000. Bremer Bank National Association acquired a new position in shares of ABIOMED in the first quarter valued at approximately $27,000. Sterling Investment Advisors Ltd. boosted its holdings in shares of ABIOMED by 233.3% in the first quarter. Sterling Investment Advisors Ltd. now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 70 shares during the period. Captrust Financial Advisors boosted its holdings in shares of ABIOMED by 1,187.5% in the fourth quarter. Captrust Financial Advisors now owns 103 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 95 shares during the period. Finally, Meridian Wealth Management LLC acquired a new position in shares of ABIOMED in the first quarter valued at approximately $40,000. Hedge funds and other institutional investors own 87.09% of the company’s stock.
ABIOMED Company Profile
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Featured Story: Using other technical indicators with support levels
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.